Directors Report for the year ended 31 December 2002 The Directors submit their annual report on the affairs of the Group, together with the financial statements and auditors report for the year ended 31 December 2002.
The Remuneration report can be found on pages 30 to 38 and the Corporate Governance report, including the Corporate Social Responsibility statement, can be found on pages 39 to 43. Review of business operations and future developments The principal activity of the Group undertaken during the year was the ongoing research and development of novel therapeutic products for human use and the manufacture and sale of prescription pharmaceutical products.
Key events during the past year are referred to in the Chairmans and Chief Executives Statement and the Group and Operational Reviews.
These events include the following: On 28 February 2002 Celltech announced outline results showing promising efficacy and safety from a large Phase II study with CDP 870 in Crohns disease patients.
On 26 March 2002 Celltech announced a strategic alliance with BioReliance for the manufacture of clinical supplies.
On 28 March 2002 Celltech announced a multi-target collaboration to use Seattle Genetics antibody-drug conjugate technology with Celltechs antibody fragments directed against specific diseases, including immunological targets.
On 24 April 2002 Celltech announced a world-wide collaboration with Biogen Inc to develop and commercialise CDP 571.
On 17 May 2002 Celltech announced an agreement with Amgen for the research, development and global commercialisation of novel treatments for osteoporosis utilising Celltechs proprietary antibody fragment technology.
On 30 July 2002 Celltech announced that it had entered into an agreement with Pharmacia Corporation to access its product Dipentum, which is marketed as a treatment for ulcerative colitis.
On 30 July 2002 Celltech announced its results from CDP 571 Phase III studies in Crohns disease.
On 12 September 2002 Celltech announced that it had entered into a long-term agreement with Biochemie, an affiliate of Novartis AG, under which Biochemie would manufacture for and supply to Celltech PEGylated antibody fragment-based drugs.
On 15 October 2002 Celltech announced results from a head-to-head trial of Metadate CD and McNeils Concerta.
On 26 November 2002 Celltech announced receipt of a $10 million milestone payment upon entry of its CDP 870 product into Phase III clinical studies.
Results and dividends Turnover for the year amounted to 329.6 million 2001: 303.1 million.
The Directors do not recommend payment of a dividend.
Directors Membership of the Board together with Directors biographies is shown on pages 26-27.
Details of Directors remuneration and their interests in the share capital of the Company are given in the Remuneration report which can be found on pages 30 to 38.
There have been no changes to Directors interests from 31 December 2002 to the date of this document, other than those set out on page 36.
Mr. Philip Rogerson 58 was appointed to the Board on 12 March 2003.
He is Chairman of Aggreko plc and Viridian Group plc and Chairman or Non-Executive Director of a number of other companies.
None of the Directors has any interest in any contract of significance.
Employees remuneration Celltech aims to provide remuneration packages that are competitive and designed to attract, retain and motivate employees.
In addition to the payment of competitive salaries, Celltech also operates two discretionary bonus schemes.
The first scheme is offered to all staff and Executive Directors.
Performance related payments may be made annually based on predetermined individual or team performance objectives.
Bonus award entitlements range between 7.5% to 40% 50% in the case of Dr Fellner of salary depending on grade.
The second scheme is a Deferred Bonus Plan under which awards may be made to selected Directors and senior executives over shares up to 100% of a participants annual bonus.
The shares subject to awards are held in the Celltech Group plc Employee Share Trust and are capable of release over a period of two years from the date of grant of an award.
All bonuses are provided for at the end of the financial year to which they relate.
Further details of Directors remuneration for the year are given in the Remuneration report.
28 Celltech Annual Report 2002 In addition, eligible employees are given the opportunity to participate in the Groups Share Option Schemes.
The allocation of share options takes into account a review of the future potential contribution of individual employees.
Employee involvement During the year, Celltech continued its policy of providing employees with information about the Group through regular presentations by Directors and the publication of an in-house magazine.
In addition, regular meetings are held between management and employees to allow a free flow of information and ideas.
Payment of creditors It is Celltechs policy with respect to the payment of its suppliers either to use standard terms or to arrange terms of payment when agreeing the terms of each transaction.
Where standard terms are not used, suppliers are made aware of the terms of payment and Celltech abides by those terms of payment.
The average number of days purchases for the Group for which payment was outstanding during the year was 38 days.
The Company has no trade creditors.
Political and charitable donations During the year Celltech made contributions amounting to 22,000 2001: 7,000 to charitable organisations in the UK.
There were no political donations 2001: nil.
Disabled employees Applications for employment by disabled persons are always fully considered, bearing in mind the aptitudes of the applicant concerned.
With regard to existing employees and those who may become disabled, Celltechs policy is to examine ways and means to provide continuing employment under its existing terms and conditions and to provide training and career development, including promotion, wherever appropriate.
Significant shareholdings As at 17 March 2003 Celltech had received notification from the following institutions of interests in 3% or more of the issued ordinary share capital of the Company.
Barclays plc 8,392,690 3.04% Fidelity International Limited 25,164,696 9.13% Franklin Resources Inc 18,260,626 6.62% Legal & General Investment Mgt Limited 8,721,325 3.16% The Capital Group Companies 20,506,734 7.44% Aviva Morley 11,576,958 4.20% Share price The mid-market share price as derived from the London Stock Exchange Daily Official List was 345p on 31 December 2002.
The mid-market share price ranged from 290p to 902p during the year 1 January 2002 to 31 December 2002 2001 financial year: 545p to 1437p.
The average share price for the year was 514.2p.
Auditor KPMG Audit plc has expressed its willingness to continue in office as Auditor and a resolution proposing its reappointment and authorising the Directors to determine its remuneration will be submitted at the Annual General Meeting AGM.
Annual General Meeting The AGM of the Company will be held at 11.30 am on Thursday 22 May 2003 at Merchant Taylors Hall, 30 Threadneedle Street, London.
Details of the business to be transacted at the AGM can be found in the separate Circular to shareholders accompanying this report.
By order of the Board J A D Slater Secretary 17 March 2003 Celltech Annual Report 2002 29
